Manufacturer of Controlled Substances, Notice of Application, Nektar Therapeutics, 64018 [2013-25079]
Download as PDF
<![CDATA[
64018
Federal Register / Vol. 78, No. 207 / Friday, October 25, 2013 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application; GE
Healthcare
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 12,
2013, GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture a
radioactive product to diagnose
Parkinson’s disease for distribution to
its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: October 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25101 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
emcdonald on DSK67QTVN1PROD with NOTICES
Manufacturer of Controlled
Substances, Notice of Application,
Stepan Company
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 7, 2013,
Stepan Company, Natural Products
Dept., 100 W. Hunter Avenue,
Maywood, New Jersey 07607, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Cocaine (9041) .............................
Ecgonine (9180) ...........................
VerDate Mar<15>2010
17:55 Oct 24, 2013
II
II
Jkt 232001
The company plans to manufacture
the listed controlled substances in bulk
for distribution to their customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: October 9, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25097 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application,
Research Triangle Institute
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 25, 2013,
Research Triangle Institute, Hermann
Building East Institute Drive, P.O. Box
12194, Research Triangle Park, North
Carolina 27709, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Tetrahydrocannabinols (7370), a class of
controlled substance listed in schedule
I.
The company plans to provide small
quantities to commercial customers for
use in preparing test kits, reagents, and
reference standards.
The company plans to bulk
manufacture a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: October 10, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25085 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application,
Nektar Therapeutics
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 16, 2013,
Nektar Therapeutics, 1112 Church
Street, Huntsville, Alabama 35801,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Fentanyl (9801), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in
support of product development.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25079 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Boehringer Ingelheim Chemicals, Inc.
By Notice dated June 18, 2013, and
published in the Federal Register on
July 1, 2013, 78 FR 39340, Boehringer
Ingelheim Chemicals, Inc., 2820 N.
Normandy Drive, Petersburg, Virginia
23805–9372, made application by
E:\FR\FM\25OCN1.SGM
25OCN1
]]>Agencies
[Federal Register Volume 78, Number 207 (Friday, October 25, 2013)]
[Notices]
[Page 64018]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-25079]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Application,
Nektar Therapeutics
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on August 16, 2013, Nektar
Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Fentanyl (9801), a basic class
of controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance in
support of product development.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODW), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 24, 2013.
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-25079 Filed 10-24-13; 8:45 am]
BILLING CODE 4410-09-P
